SARS-CoV-2 antibody prevalence, correlates, and access to harm reduction services among people who inject drugs living with and without HIV and their partners in Kenya

Harm Reduction Journal

Research

Shradha Doshi¹  Bhavna H. Chohan²  Aliza Monroe-Wise³  Joshua T. Herbeck³  Ashley S. Tseng⁴  Brandon L. Guthrie⁴  Hanley Kingston⁴  Carey Farquhar⁵  Sarah Masyuko⁶  Khai Hoan Tram⁷  David Bukusi⁸  William Sinkele⁹  Betsy Sambai^1,10  Paul Macharia^1,10  Loice W. Mbogo^1,10 

[1] Aga Khan University Hospital, Nairobi, Kenya;Department of Global Health, University of Washington, Seattle, WA, USA;Department of Epidemiology, University of Washington, Seattle, WA, USA;Kenya Medical Research Institute, Nairobi, Kenya;Department of Global Health, University of Washington, Seattle, WA, USA;Department of Global Health, University of Washington, Seattle, WA, USA;Department of Epidemiology, University of Washington, Seattle, WA, USA;Department of Global Health, University of Washington, Seattle, WA, USA;Department of Epidemiology, University of Washington, Seattle, WA, USA;University of Washington-Global Assistance Programme, Nairobi, Kenya;Department of Medicine, University of Washington, Seattle, WA, USA;Department of Global Health, University of Washington, Seattle, WA, USA;Ministry of Health, Nairobi, Kenya;Department of Medicine, University of Washington, Seattle, WA, USA;Kenyatta National Hospital, Nairobi, Kenya;Support for Addiction Prevention and Treatment in Africa, Nairobi, Kenya;University of Washington-Global Assistance Programme, Nairobi, Kenya;

关键词: SARS-CoV-2 antibody;    HIV/AIDS;    Sub-Saharan Africa;    PWID;    Kenya;   

DOI  :  10.1186/s12954-023-00754-5

 received in 2022-10-26, accepted in 2023-02-09,  发布年份 2023

来源: Springer

【 授权许可】

CC BY   
© The Author(s) 2023